Lab Information

Chen Liang (PhD)

Associate Investigator
Centre for Translational Biology
Department of Medicine (McGill)

Research Profile

 Fundamental: 100%
 Clinical: 0%
 Epidemiology: 0%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.


HIV • COVID-19 • SARS-CoV • innate immunity • interferon • antivirals

Research Interests

My research aims to understand the host innate immune responses to viral infections. My team uses the findings to understand viral pathogenesis and transmission and to guide the development of effective antiviral therapeutics. Specifically, we investigate how host cells produce antiviral interferons in response to infections by HIV or SARS-CoV-2, and how these two highly pathogenic viruses overcome and evade this first line of host defense. We are dedicated to the discovery of new HIV treatments and the compounds that can effectively inhibit SARS-CoV-2 and thus cure COVID-19. My lab has also pioneered the application of the CRISPR gene editing tool in curing HIV infection.

Team Members

Name Position

Latest Publications

  1. Solomon, M. & Liang, C. (2023). Pseudotyped Viruses for Retroviruses. Advances in experimental medicine and biology, vol. 1407, p. 61-84.
  2. Ma, L., Li, Y., Shi, T., Zhu, Z., Zhao, J., Xie, Y., Wen, J., Guo, S., Wang, J., Ding, J., Liang, C., Shan, G., Li, Q., Ge, M. & Cen, S. (2023). Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, vol. 158, p. 114213.
  3. Guo, S., Lei, X., Chang, Y., Zhao, J., Wang, J., Dong, X., Liu, Q., Zhang, Z., Wang, L., Yi, D., Ma, L., Li, Q., Zhang, Y., Ding, J., Liang, C., Li, X., Guo, F., Wang, J. & Cen, S. (2022). SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis. Signal transduction and targeted therapy, vol. 7, p. 400.
  4. An, N., Ge, Q., Shao, H., Li, Q., Guo, F., Liang, C., Li, X., Yi, D., Yang, L. & Cen, S. (2022). Interferon-inducible SAMHD1 restricts viral replication through downregulation of lipid synthesis. Frontiers in immunology, vol. 13, p. 1007718.
  5. Xu, F., Wang, G., Zhao, F., Huang, Y., Fan, Z., Mei, S., Xie, Y., Wei, L., Hu, Y., Wang, C., Cen, S., Liang, C., Ren, L., Guo, F. & Wang, J. (2022). IFITM3 Inhibits SARS-CoV-2 Infection and Is Associated with COVID-19 Susceptibility. Viruses, vol. 14.
  6. Siavash Moakhar, R., Del Real Mata, C., Jalali, M., Shafique, H., Sanati, A., de Vries, J., Strauss, J., AbdElFatah, T., Ghasemi, F., McLean, M., I Hosseini, I., Lu, Y., Yedire, S. G., Mahshid, S. S., Tabatabaiefar, M. A., Liang, C. & Mahshid, S. (2022). A Versatile Biomimic Nanotemplating Fluidic Assay for Multiplex Quantitative Monitoring of Viral Respiratory Infections and Immune Responses in Saliva and Blood. Advanced science (Weinheim, Baden-Wurttemberg, Germany), p. e2204246.
  7. Zhao, F., Xu, F., Liu, X., Hu, Y., Wei, L., Fan, Z., Wang, L., Huang, Y., Mei, S., Guo, L., Yang, L., Cen, S., Wang, J., Liang, C. & Guo, F. (2022). SERINC5 restricts influenza virus infectivity. PLoS pathogens, vol. 18, p. e1010907.
  8. Mei, S., Fan, Z., Liu, X., Zhao, F., Huang, Y., Wei, L., Hu, Y., Xie, Y., Wang, L., Ai, B., Liang, C., Xu, F. & Guo, F. (2022). Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate. Frontiers in immunology, vol. 13, p. 911164.
  9. Solomon, M. & Liang, C. (2022). Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19. Virus research, vol. 319, p. 198882.
  10. Beaudoin-Bussières, G., Arduini, A., Bourassa, C., Medjahed, H., Gendron-Lepage, G., Richard, J., Pan, Q., Wang, Z., Liang, C. & Finzi, A. (2022). SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity. Viruses, vol. 14.
More on PubMed 

See also

Card image

See profile